Please login to the form below

Not currently logged in
Email:
Password:

GLP-1

This page shows the latest GLP-1 news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s semaglutide obesity trial hits the mark

Novo Nordisk’s semaglutide obesity trial hits the mark

Novo Nordisk’s run of good news with GLP-1 agonist semaglutide has continued with a mid-stage trial showing it can achieve significant weight loss in adults with obesity. ... Overall, 83% of patients treated with the drug lost 5% or more of their body

Latest news

More from news
Approximately 12 fully matching, plus 136 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    These efforts moved up a gear last year when Novo decided to enter into phase III trials with an oral GLP-1.

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    like peptide-1 (GLP-1), a hormone that works independently of insulin to stimulate glucose release. ... Oramed - whose technology relies on encapsulating the peptide or protein and delivering it alongside enzyme inhibitors and permeation enhancers - has

  • Deal Watch November 2015 Deal Watch November 2015

    Included in the package are three products: a weekly insulin, a fixed weekly dose combination of GLP-1-RA/insulin and efpeglenatide, a long acting glucagon like peptide-1 receptor agonist. ... 6, 546. Hanmi Pharmaceutical. Sanofi. Licence. Three diabetes

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    400. Inarcia therapeutics / Investors. Synthetic royalty rights. ICTA650 extended sub-cutaneous delivery of GLP-1 for T2DM.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142. Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics